Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain

Yonsei University1 site in 1 country58 target enrollmentNovember 2, 2022

ConditionsAdult Patients Aged 19-64, Scheduled for Elective Arthroscopic Knee Surgery

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Adult Patients Aged 19-64, Scheduled for Elective Arthroscopic Knee Surgery
Sponsor: Yonsei University
Enrollment: 58
Locations: 1
Primary Endpoint: Intraoperative remifentanil requirement
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to investigate whether the use of nociception monitoring during general anesthesia with remimazolam-based total intravenous anesthesia has an effect on intraoperative opioid requirements and postoperative pain. This study is a randomized trial with a 50% probability of being assigned to either group. Randomization will be done by an anesthesiologist not involved in anesthesia or postoperative outcome assessment. Patients and the investigator in charge of postoperative outcomes assessment will be blinded to group allocation.

Registry

clinicaltrials.gov

Start Date

November 2, 2022

End Date

November 1, 2024

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Yonsei University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Adult patients between 19 and 64 years of age, ASA class I\~III, scheduled for arthroscopic knee surgeryunder general anesthesia.

Exclusion Criteria

•Patient refusal, patients unable to read consent form, active URI or uncontrolled asthma, pneumonia, history of allergies to benzodiazepines, decreased liver or kidney function, heart failure of ejection fraction\<55%, pregnant or breastfeeding patients, history of substance abuse/addiction